You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Baxter
Colorcon
Harvard Business School

Last Updated: January 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Raltitrexed

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Raltitrexed?

Raltitrexed is an investigational drug.

There have been 40 clinical trials for Raltitrexed. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Cancer Institute (NCI), and Jiangsu Cancer Institute & Hospital.

There are eighty-three US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Raltitrexed
TitleSponsorPhase
TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCBeijing Cancer HospitalPhase 2
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerShanxi Province Cancer HospitalPhase 2
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerFudan UniversityPhase 2

See all Raltitrexed clinical trials

Clinical Trial Summary for Raltitrexed

Top disease conditions for Raltitrexed
Top clinical trial sponsors for Raltitrexed

See all Raltitrexed clinical trials

US Patents for Raltitrexed

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Raltitrexed   Start Trial Inhibition of hypoxia-inducible factor activity with carica papaya extracts The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY)   Start Trial
Raltitrexed   Start Trial Assay for predictive biomarkers Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
Raltitrexed   Start Trial 2-aminopyrimidine compound and pharmaceutical composition and use thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, CN) GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (Guangzhou, CN)   Start Trial
Raltitrexed   Start Trial Devices, systems and methods for treating benign prostatic hyperplasia and other conditions NeoTract, Inc. (Pleasanton, CA)   Start Trial
Raltitrexed   Start Trial Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules MEDICUS BIOSCIENCES, LLC (San Francisco, CA)   Start Trial
Raltitrexed   Start Trial Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)   Start Trial
Raltitrexed   Start Trial Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Raltitrexed

Drugname Country Document Number Estimated Expiration Related US Patent
Raltitrexed Canada CA2907124 2033-03-15   Start Trial
Raltitrexed China CN105308186 2033-03-15   Start Trial
Raltitrexed European Patent Office EP2971101 2033-03-15   Start Trial
Raltitrexed Israel IL241063 2033-03-15   Start Trial
Raltitrexed Japan JP2016514827 2033-03-15   Start Trial
Raltitrexed Japan JP6663347 2033-03-15   Start Trial
Raltitrexed South Korea KR20150132206 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
Baxter
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.